Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while YieldMax TSLA Option Income Strategy ETF trades at $21.12 (market cap $675.95M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 11.1× YieldMax TSLA Option Income Strategy ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and YieldMax TSLA Option Income Strategy ETF for 45 Days on average.
| SYRE | TSLY | |
|---|---|---|
Market Cap | $7.52B | $675.95M |
Volume | 1,441,031 | 216,837 |
Sector | Health | Income / Options Overlay |
52-Week High | $108.92 | $43.35 |
52-Week Low | $22.18 | $20.49 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TSLY trades at $22.11, down 0.58% with a bearish technical signal from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent news highlights concerns about underperformance relative to Tesla's stock gains. Technical indicators show neutral oscillators with key support at $22 and resistance at $23.
The outlook remains cautious as TSLY faces structural challenges capturing Tesla's upside while providing income. Investors should weigh the high dividend yield against potential capital erosion during Tesla rallies. Key risks include volatility regime changes and the ETF's option strategy limitations in strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
